Bharat Biotech's Covaxin has demonstrated 77.8 per cent effectiveness against symptomatic COVID-19 and 65.2 per cent protection against the new Delta variant.
The panel was informed that the economic impact of the second wave of viral infection was "asynchronous in its onset and wider in its spread particularly in rural hinterland", a source said.
The results of blood samples of the student, which were tested at the National Institute of Virology in Pune, have confirmed Nipah, she said.
Maharashtra reported seven new cases of the Omicron variant of coronavirus on Friday including a three-and-half-year-old girl which took the tally of such infections to 17, the state health department said.
The average Tests Per Million Per Day have increased from 237 in the second week of July to 758 in the first week of September.
'I can say with confidence that any future SARS-CoV-2 vaccine, developed anywhere in the world, would have to be manufactured in India, if it is to be affordable and of high quality.'
After the outbreak of Nipah at a hamlet in Perambra last week, 16 people have tested positive, of whom 13 have died so far.
But that does not mean that we are lowering our guard. The (28-day) quarantine period will continue.
Covaxin is being developed by Bharat Biotech jointly with the Indian Council of Medical Research (ICMR)- National Institute of Virology (NIV). The Phase III human clinical trials of Covaxin began mid-November, targeted to be done in 26,000 volunteers and it is the country's first and only Phase III efficacy study for a COVID-19 vaccine, a press release from the vaccine maker said on Saturday night.
"The intelligence community and the rest of the government are still looking at this. There's not been a definitive conclusion, so it's difficult for me to say, nor should I feel like I should have to defend press reporting about a possible preliminary indication here," National Security Council Coordinator for Strategic Communications John Kirby told reporters at a daily White House news conference.
Omicron has been detected in Maharashtra (20), Rajasthan (9), Karnataka (3), Gujarat (4), Kerala (1) and Andhra Pradesh (1) and Union Territories of Delhi (2) and Chandigarh (1).
The fact sheet also asked people to inform the vaccinator or a supervising official about their medical condition before taking the vaccine.
According to these experts, a monkeypox outbreak can effectively be tackled by strong surveillance.
The decline in the effectiveness of Covaxin, India's indigenous COVID-19 vaccine, from 77.8 per cent to 50 per cent during a Delta-driven case surge in April and May this year is neither bad nor surprising, say scientists.
Of the fresh cases, two were natives of Anayara in Thiruvananthapuram, where a cluster of the disease had been identified within a three kilometre radius, Health Minister Veena George said.
Vaccine major Bharat Biotech on Wednesday said its COVID-19 vaccine, Covaxin, has demonstrated an interim vaccine efficacy of 81 per cent in the Phase 3 clinical trials.
Ahmedabad was the first stop in the PM's three city tour today, to personally review the vaccine development and manufacturing process in the country.
The New York Times on Tuesday said Covaxin works by teaching the immune system to make antibodies against the SARS-CoV-2 coronavirus. The antibodies attach to viral proteins, such as the so-called spike proteins that stud its surface.
Safety and Efficacy results from the final analysis will be available in June, and the final report will be submitted to a peer-reviewed publication.
The minister said there has been no cases of Nipah reported from anywhere in the country
Highlighting that mutation in a virus is a natural phenomenon, the civic body said citizens should do not panic and appealed to them to follow COVID-19-appropriate behaviour.
Amid a spike in coronavirus infection in parts of Maharashtra, Mumbai has witnessed 36.38 per cent rise in the active COVID-19 cases since February 8, as per the city civic body.
The hospital where the boy was being treated since September 1 is on alert and the situation there was being closely monitored, sources said.
Eight new cases of the Omicron variant of coronavirus were reported in Maharashtra -- seven of them in Mumbai -- and none of the patients had a history of international travel, the state health department said on Tuesday.
They include a woman who came from Nigeria along with her two daughters to meet her brother in adjoining Pimpri Chinchwad area, the official said.
The Central Drugs Standard Control Organisation has granted restricted emergency use authorisation to two new vaccines and a drug for COVID-19, taking the number of preventives and treatments available in India to 12.
The man had attended a stag party recently in Manali in Himachal Pradesh.
He said in the last 8-10 days, the active cases in the state stood in the range of 5,000-6,000.
In phase I, the vaccine would be tested on 375 volunteers and the maximum of 100 of them would be from AIIMS.
The new report highlights how different parts of the intelligence community have arrived at disparate judgments about the pandemic's origin.
ICMR's serological survey, whose findings will be made public next week, suggests that the rate of contagion may be a lot higher in most-affected cities such as Delhi, Mumbai, and Pune.
The government said it looks at such studies with due respect but it is yet to examine whether this particular report has a scientific worth or not.
Maharashtra government has deployed ambulances available with the state emergency medical service at the city's international airport to shift suspected Ebola Virus Disease passengers.
The Centre has warned it is likely that the spread of the new variant will outpace the Delta variant where there is community transmission.
The Drugs Control General of India has permitted emergency use of Covid vaccine Sputnik V with certain conditions, clearing the way for a third vaccine in addition to Covishield and Covaxin. Besides, the government on Tuesday also fast-tracked emergency approval for other jabs. Here is what the vaccines are all about:
Results of an interim study recently published in The Lancet showed that two doses of Covaxin, also known as BBV152, had 77.8 per cent efficacy against symptomatic disease and present no serious safety concerns.
Tamil Nadu, Telangana and West Bengal reported their first COVID-19 variant Omicron cases on Wednesday, four more persons each tested positive in Maharashtra and Kerala.
The vaccine candidate, ZyCoV-D, showed a "strong immune response" in animal studies, and the antibodies produced were able to completely neutralise the wild type virus, Zydus said. The 12 institutes have been asked by the ICMR to fast track clinical trials of the vaccine as it is being considered as one of the top priority projects which are being monitored at the topmost level of the government.
'It came out of China and it could have been stopped and I wish they had stopped it and so does the whole world wish they had stopped it'
The ministry said 151 out of the 578 people who contracted the infection have recovered or migrated.
